Vascular endothelial growth factor in persons with type 2 diabetes
Authors:
J. Staško 1; P. Chudý 1; D. Mištuna 3; P. Galajda 2; M. Mokáň 2; P. Kubisz 1
Authors‘ workplace:
Národné centrum hemostázy a trombózy, Klinika hematológie a transfuziológie Jesseniovej lekárskej fakulty Univerzity Komenského (JLF UK) a Martinskej fakultnej nemocnice (MFN), Martin, SR
1; I. interná klinika JLF UK a MFN, Martin, SR
2; I. chirurgická klinika JLF UK a MFN, Martin, SR
3
Published in:
Transfuze Hematol. dnes,15, 2009, No. 3, p. 152-157.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Aim of the study was to investigate the relationship between the serum vascular endothelial growth factor concentration and parameters of endothelial injury and/or dysfunction in persons with type 2 diabetes mellitus with normo- or microalbuminuria.
Patients and methods:
Eighty-four persons with type 2 diabetes were divided in two subgroups (n = 42 each): normoalbuminuric and microalbuminuric. Forty-two blood donors were in control group. Serum vascular endothelial growth factor and the plasma concentrations of von Willebrand factor, soluble thrombomodulin, plasminogen activator inhibitor type 1, thrombin-activatable fibrinolysis inhibitor and tissue plasminogen activator were measured using enzyme-linked immunosorbent assay (ELISA) in all subjects.
Results:
The vascular endothelial growth factor concentration was significantly higher in normoalbuminuric diabetic group compared to controls (338.5, 202-432 pg/mL vs. 182, 124-211 pg/ml, p = 0.0443). The difference between microalbuminuric diabetic group and controls was not statistically significant.
Conclusions:
Serum vascular endothelial growth factor could be a more sensitive predictor of renal vascular changes in persons with diabetes mellitus type 2 than microalbuminuria.
Key words:
vascular endothelial growth factor, diabetes mellitus type 2, microalbuminuria, endothelial dysfunction, endothelial markers
Sources
1. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003–2017.
2. Clayton JA, Chalothorn D, Faber JE. Vascular endothelial growth factor-A specifies formation of native collaterals and regulates collateral growth in ischemia. Circ Res 2008; 103: 1027–1036.
3. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron-Physiology 2007; 106: 26–31.
4. Khamaisi M, Schrijvers BF, De Vriese AS, Raz I, Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 2003; 18: 1427–1430.
5. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000; 43: 1205–1223.
6. Chiarelli F, Spagnoli A, Basciani F, et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabetes UK. Diabet Med 2000; 17: 650–656.
7. Knöbl P, Schernthaner G, Schnack C, et al. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1045–1050.
8. Santilli F, Spagnoli A, Mohn A, et al. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 2001; 86: 3871–3876.
9. Hovind P, Tarnow L, Oestergaard PB, Parving HH. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57 (Suppl 75): S56–S61.
10. Wasada T, Kawahara R, Katsumori K, Naruse M, Omori Y. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 1998; 47: 27–30.
11. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci 2002; 102: 187–194.
12. Shimada K, Baba T, Neugebauer S, et al. Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy. J Diabetes Complications 2002; 16: 386–390.
13. Kim NH, Kim KB, Kim DL, et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabetes UK. Diabet Med 2004; 21: 545–551.
14. Kim NH, Oh JH, Seo JA, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005; 67: 167–177.
15. Cha DR, Kang YS, Han SY, et al. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 2004; 183: 183– 194.
16. Heywood DM, Mansfield MW, Grant PJ. Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 1996;13: 720–725.
17. Collier A, Rumley A, Rumley AG, et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992; 41: 909–13.
18. Schmitz A, Ingerslev J. Haemostatic measures in type 2 diabetic patients with microalbuminuria. Diabet Med 1990; 7: 521–525.
19. Gabat S, Keller C, Kempe HP, et al. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus. Vasa 1996; 25: 233–241.
20. Inukai T, Fujiwara Y, Tayama K, Aso Y, Takemura Y. Clinical significance of measurements of urinary and serum thrombomodulins in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1996; 33: 99–104.
21. Nilsson TK, Hellsten G, Amiral J. Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis 1993; 4: 455–458.
22. Yano Y, Kitagawa N, Gabazza EC, et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88: 736–741.
23. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002; 25: 1340–1345.
24. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15: 1114–1120.
25. Gruden G, Cavallo-Perin P, Romagnoli R, Olivetti C, Frezet D, Pagano G. Prothrombin fragment 1 + 2 and antithrombin III-thrombin complex in microalbuminuric type 2 diabetic patients. Diabet Med. 1994; 11: 485–488.
26. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report. Diabetes Care 2003; 26 (Suppl 1): S5–S20.
27. McLaren M, Elhadd TA, Greene SA, Belch JJ. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Apll Thromb Haemost 1999; 5: 21–24.
28. Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP. EUCLID Study Group. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 2001; 18: 288–294.
29. Sharp PS, Al-Mrayat M, Valabhji J, Kearney TM, Wright D. Serum levels of vascular endothelial growth factor in diabetic subjects: the relationship with blood pressure. Diabetologia 1998; 41: 984–985.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 3
Most read in this issue
- Detection of the JAK2V617F mutation in myeloproliferative disorders - an overview and own experiences
- Successful treatment of early molecular relapse of variant form of secondary acute promyelocytic leukemia with arsenic trioxide
- Warfarin-induced skin necrosis, case report and survey of resources
- The role of positron emission tomography and combined positron emission tomography with computed tomography in staging and response assessment in patients with non-Hodgkin’s lymphoma. Part II: Response evaluation